



(51) International Patent Classification:

C07D 207/263 (2006.01) **A61K 31/4015** (2006.01)
C07C 269/06 (2006.01) **C07D 207/36** (2006.01)
C07C 271/22 (2006.01)

(21) International Application Number:

PCT/EP2009/050510

(22) International Filing Date:

16 January 2009 (16.01.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

08150353.4 17 January 2008 (17.01.2008) EP

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) **Inventors/Applicants (for US only):** **HOOK, David** [GB/CH]; Im Kunzentel 26, CH-4310 Rheinfelden (CH). **RISS, Bernhard** [FR/FR]; Rue du Dr. Mangeney 44, F-68330 Huningue (FR). **KAUFMANN, Daniel** [CH/CH]; Chlederenweg 22, CH-4112 Bättwil (CH). **NAPP, Matthias** [DE/DE]; Pestalozzistrasse 57, 79540 Lörrach (DE). **BAPPERT, Erhard** [DE/CH]; Vogesenstrasse 72, CH-4056 Basel (CH). **POLLEUX, Philippe** [FR/CH]; Gartengasse 9, CH-4125 Riehen (CH). **MEDLOCK, Jonathan** [GB/GB]; Johnson Matthey, Catalysis and Chiral Technologies, Cambridge Science Park, Unit 28, Cambridge Cambridgeshire CB4 0FP (GB). **ZANOTTI-GEROSA, Antonio** [IT/GB]; Johnson Matthey, Catal-

ysis and Chiral Technologies, Cambridge Science Park, Unit 28, Cambridge Cambridgeshire CB4 0FP (GB).

(74) Agent: **DIETEL, Anja**; Novartis Pharma AG, Patent Department, CH-4002 Basel (CH).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

[Continued on next page]

(54) Title: PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 5-BIPHENYL-4-YL-2-METHYLPENTANOIC ACID DERIVATIVES



(57) **Abstract:** The invention relates to a process for producing NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ -amino- δ -biphenyl- α -methylalkanoic acid, or acid ester, backbone. In detail, the new processes, according to the present invention, are ultimately related to the synthesis of intermediates to prepare the above NEP inhibitors, namely compounds according to formula (1), or salt thereof, wherein R1 and R2 are, independently of each other, hydrogen or a nitrogen protecting group, and R3 is a carboxyl group or an ester group, preferably carboxyl group or alkyl ester.



(88) Date of publication of the international search report:

23 December 2009